gefitinib resistant
Targeting the degradation of AXL receptor tyrosine kinase to overcome resistance in gefitinib-resistant non-small cell lung cancer
... suggested that the activation of AXL is associated with TKI-resistance in several cancers, such as gastrointestinal stromal tumors, ovarian cancer, triple-negative breast cancer and chronic myeloid leukemia [24–26]. We ...
15
Antitumor activity of selective MEK1/2 inhibitor AZD6244 in combination with PI3K/mTOR inhibitor BEZ235 in gefitinib-resistant NSCLC xenograft models
... and MEK5/ERK5 pathways and is currently in phase II clinical trial in KRAS-mutant NSCLC [9,10]. In vivo, AZD6244 could inhibit the tumor growth in HT-29 xenograft model, which is a colorectal tumor model car- rying a ...
10
Short-hairpin RNA library: identification of therapeutic partners for gefitinib-resistant non-small cell lung cancer
... with gefitinib in NSCLC ...with gefitinib in tyrosine kinase inhibitor resistant ...with gefitinib synergistically inhibited the growth of NSCLC ...with gefitinib to reduce p-Akt levels ...
11
Heregulin β1 drives gefitinib resistant growth and invasion in tamoxifen resistant MCF 7 breast cancer cells
... inhibitors gefitinib (Iressa, ZD1839) and erlotinib (Tarceva, OSI-774), which competi- tively block binding of ATP to the tyrosine kinase domain of the receptor ...cetuximab, gefitinib and erlotinib have ...
14
FOXM1 confers resistance to gefitinib in lung adenocarcinoma via a MET/AKT-dependent positive feedback loop
... in gefitinib resistance of lung cancer cells [35, ...in gefitinib-resistant lung adenocarcinoma cells and FOXM1 can stimulate MET/AKT pathway in a positive-feedback manner strongly suggest that FOXM1 ...
15
244-MPT overcomes gefitinib resistance in non-small cell lung cancer cells
... both gefitinib- sensitive and –resistant NSCLC cell lines (Figure 1C, ...human gefitinib-sensitive tumors established a gefitinib- resistant NSCLC PDX mouse ...reduce ...
15
Irmer, Denis Joachim (2008): Molecular analyses of resistance and sensitivity mechanisms to anti-EGFR directed tumor therapy. Dissertation, LMU München: Fakultät für Chemie und Pharmazie
... In addition, this work could show that HGFR-specific TKIs cause an appreciable growth inhibition in A431 cells that were long-term treated with cetuximab, but not in the gefitinib-resistant population or ...
160
Original Article Mig-6 overcomes gefitinib resistance by inhibiting EGFR/ERK pathway in non-small cell lung cancer cell lines
... inhibitor gefitinib is widely used for patients with advanced ...and gefitinib sensitivity, nor has the contribution of up-regulated Mig-6 on the gefitinib-resistant cell ...to ...
8
Original Article Decitabine reverses gefitinib resistance in PC9 lung adenocarcinoma cells by demethylation of RASSF1A and GADD45β promoter
... acquired gefitinib resistant lung adenocarcinoma cell line PC9/ GR, induce a partial restoration of RASSF1A and GADD45β protein expression, and partially reverse the gefitinib resistance of the cell, ...
9
Original Article Connexin 43 affects intrinsic gefitinib resistance of NSCLC cells by GJIC
... Abstract: Gefitinib efficiency in non-small-cell lung cancer (NSCLC) therapy is limited as a majority of NSCLC cells with no epidermal growth factor receptor (EGFR) mutations are intrinsic gefitinib ...
7
IL-8 confers resistance to EGFR inhibitors by inducing stem cell properties in lung cancer
... that gefitinib-resistant cells (PC9/gef) exhibited stem- like characteristics, such as high potential for sphere formation, expression of stemness-related genes, and ALDH activity ...from ...
17
Exosome-mediated transfer of lncRNA PART1 induces gefitinib resistance in esophageal squamous cell carcinoma via functioning as a competing endogenous RNA
... Fig. 7 LncRNA PART1 mediates Bcl-2 expression through functioning as a ceRNA for miR-129. a Presentation of score of lncRNA PART1 at different subcellular locations by lncLocator ...
16
Curcumin overcome primary gefitinib resistance in non-small-cell lung cancer cells through inducing autophagy-related cell death
... cluding gefitinib, erlotinib and afatinib) produce marked tumor response and improved progression-free survival (PFS) in NSCLC patient harboring activating EGFR mu- tation [4, 43], patients with wild-type EGFR and ...
17
Rhodomycin A, a novel Src-targeted compound, can suppress lung cancer cell progression via modulating Src-related pathways
... rendered gefitinib-resistant lung adenocarcinoma cells more sensitive to gefitinib treatment, implying a synergistic effect of the combination ...
14
Inhibition of SREBP increases gefitinib sensitivity in non-small cell lung cancer cells
... MARVELD1 is previously reported as a drug- resistant related protein [10]. Here, we validated the interaction between SREBP and MARVELD1 by co-immunoprecipitation (Figure 2A). Pull-down showed MARVELD1 only bound ...
12
Hepatocyte growth factor reduces sensitivity to the epidermal growth factor receptor-tyrosine kinase inhibitor, gefitinib, in lung adenocarcinoma cells harboring wild-type EGFR
... antibiotic-free medium were plated into 24-well plates. After incubation for 24 h, the cells were transfected with small interfering RNA (siRNA; 50 µmol) or scramble RNA using Lipofectamine 2000 (1 µL) in accordance with ...
9
Involvement of the epidermal growth factor receptor in the modulation of multidrug resistance in human hepatocellular carcinoma cells in vitro
... drug resistant cells were evaluated with RT-PCR and MTT ...of resistant cells was increased after activation of the tyro- sine kinase pathway in a time-dependent ...
9
Overexpression of OCT4 is associated with gefitinib resistance in non-small cell lung cancer
... Cells were treated with different concentrations of gefitinib. Western blot was performed as described elsewhere. Primary antibodies used were as follows: OCT4 (Abcam, Cambridge, MA, USA), GAPDH (Cell Signaling ...
6
Gefitinib for advanced non small cell lung cancer
... We assessed the eligibility of retrieved articles from the title and abstract. Two investigators (ES, IY) reviewed potential trials for inclusion and extracted data from the published manuscripts. We resolved ...
270
GPR119 agonist enhances gefitinib responsiveness through lactate-mediated inhibition of autophagy
... in gefitinib-treated MCF-7 cells, and the number of GFP puncta was diminished by MBX-2982 treatment ...of gefitinib, whereas tumor growth was completely suppressed by co-administration of gefi- tinib with ...
15